DAXOR CORP - 10-Q Summary (Q1 2003)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2003. DAXOR Corporation operates in the medical technology sector, focusing on the Blood Volume Analyzer (BVA) and providing localized semen and blood banking services. The company is actively expanding its sales and marketing infrastructure to promote the BVA as a standard of care.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 |
|---|---|---|
| Total Revenues | $737,617 | $661,838 |
| Operating Revenues | $218,683 | $193,063 |
| Net Income / (Loss) | $(274,585) | $32,574 |
| EPS (Basic) | $(0.06) | $0.01 |
| Cash from Operations | $(281,708) | $66,229 |
| Total Assets | $39,272,928 | N/A |
| Total Liabilities | $7,743,700 | N/A |
| Shareholders' Equity | $31,529,228 | N/A |
| Marketable Securities (Fair Value) | $38,195,080 | N/A |
| Loans Payable | $1,922,605 | N/A |
Note: Operating expenses ($990,652) significantly exceeded total revenues, resulting in a net loss. The company holds a substantial portfolio of marketable securities with a net unrealized gain of $16,174,210.
Material Changes vs. Prior Period
- Profitability: The company shifted from a net profit of $32,574 in Q1 2002 to a net loss of $274,585 in Q1 2003.
- Revenue Composition: While operating revenues increased by approximately 13% (driven by the BVA Division), the majority of total revenue ($479,889) remains derived from dividend income on investments.
- Expense Growth: Selling, General, and Administrative (SG&A) expenses surged from $399,198 to $638,886, reflecting increased investment in sales and marketing staff.
- Liquidity: Cash and cash equivalents increased from $13,035 to $37,460, supported by a $200,000 bank loan receipt and net proceeds from investment activities.
- Debt: Loans payable increased from $1,434,046 to $1,922,605, including margin debt secured by marketable securities.
Outlook, Risks, and Management Commentary
- Strategic Focus: Management anticipates that increased sales and marketing expenses will yield results in the second quarter. The sales cycle for hospital and physician adoption is estimated at 6 to 12 months.
- Expansion Plans: The company plans to hire 2 to 3 additional regional managers and expand support services. It is also evaluating blood volume instrumentation management programs and private label leasing options.
- Capital Strategy: The company relies on its investment portfolio (primarily utility stocks) for liquidity. It utilizes an "instrument loaner reagent plan" to lower customer entry barriers, though this slows the return on capital expenditure.
- Risks: The business model is heavily dependent on the performance of its investment portfolio for revenue stability. There are no current legal proceedings.
Investor Verification Checklist
- Investment Portfolio Volatility: Verify the current fair value of the $38.2M marketable securities portfolio, as unrealized gains constitute a significant portion of Shareholders' Equity.
- Sales Cycle Realization: Monitor Q2 and Q3 results to confirm if the increased SG&A spending translates into accelerated operating revenue growth as projected.
- Debt Covenants: Review the terms of the $1.9M in loans payable, specifically the margin debt secured by securities, to assess liquidity risks if the portfolio value declines.
- Operating Margin: Assess the trajectory of the "Operations of Laboratories & Costs of Production" line item, which rose significantly to $337,259, to determine if unit economics are improving.